I. Introduction
Personalized medicine, also known as precision or individualized medicine, is a rapidly evolving field where medical decisions are tailored to individual patients based on their genetic and genomic data. This approach extends conventional medicine, which applies one strategy across all patients without tailoring to personal genetic and genomic information.
In the fast-paced world of healthcare, the revolutionary approach known as personalized medicine is ushering in a new era that promises to transform the way we prevent, diagnose, and treat diseases. This paradigm shift leverages the power of individualized genetic and genomic information to tailor medical interventions for each patient.
II. Origins of Personalized Medicine
The concept of personalized medicine materialized in the 1990s, following advances in DNA sequencing technology. The Human Genome Project (HGP; 1990-2003) and the International HapMap Project (2002-10) were significant milestones that provided researchers with the information needed to associate gene variants with specific diseases and disorders. The completion of the Human Genome Project in 2003 was a pivotal moment, providing researchers with a comprehensive map of the human genome. This monumental achievement laid the foundation for the emergence of personalized medicine by unraveling the intricate genetic code that influences our susceptibility to diseases and response to treatments.
At its core, personalized medicine relies on the analysis of an individual's genetic makeup to inform medical decisions. Unlike traditional approaches that apply broad treatment strategies, personalized medicine takes into account the unique genetic variations present in each patient. This tailored approach allows healthcare professionals to predict how a person might respond to a specific treatment, offering the potential for more effective and targeted interventions.
III. Personalized Medicine Examples
Personalized medicine is used in various ways to facilitate the prevention, diagnosis, and treatment of disease. Here are some notable examples:
1. Tumor Marker Testing: This method is used to treat cancer by identifying specific mutations that drive certain cancers.
2. Genome Sequencing: The process of determining the entire genetic makeup of a specific organism or type of cell.
3. Pharmacogenomics: This field studies how individuals react differently to medicines. Scientists can now identify glitches in our DNA scripts that reveal what drugs may be dangerous, or completely ineffective, for certain people.
IV. Routine Practice
Personalized medicine is increasingly becoming a reality in medical practice. Here are some relevant examples:
1. Risk Assessment: Through network analysis, scientists pinpointed 10 seed genes, 22 associated genes, 132 microRNAs, and 38 transcription factors directly influencing all types of epilepsy and seizures. Upon functional analysis, the majority of seed genes were notably associated with the acetylcholine-gated channel complex (10%) and the heterotrimeric G-protein complex (10%) pathways concerning cellular components. Additionally, these genes play key roles in the regulation of action potential (20%) and positive regulation of vascular endothelial growth factor production (20%) within pathways related to biological processes in epilepsy and seizures. [Chouhan, 2024]
The study sheds light on the disease's inner workings, emphasizing the importance of ongoing research into epilepsy and related conditions triggering seizure activity. Understanding the specific pathways and components involved offers valuable insights, potentially guiding future interventions and deepening our comprehension of epilepsy's intricacies. Continued exploration in this field holds the promise of advancing therapeutic strategies and improving outcomes for those affected by epilepsy and seizures. [Chouhan, 2024]
2. Avoiding Adverse Reactions : Gefitinib stands out as a potent and selective oral inhibitor of the growth factor receptor (EGFR) tyrosine kinase. It is widely employed in the treatment of advanced non-small cell lung cancer among patients exhibiting activating EGFR mutations. ...
(All Rights Reserved)